Compare Manhattan Associates Inc (MANH) vs Tempus AI (TEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Manhattan Associates Inc vs Tempus AI — how do they compare? Manhattan Associates Inc trades at $206.18 (market cap $11.79B), while Tempus AI trades at $70 (market cap $12.77B). The key difference: Manhattan Associates Inc and Tempus AI are close in size by market cap, and Manhattan Associates Inc is trading nearer its 52-week high, Tempus AI nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Manhattan Associates Inc for 12 Days and Tempus AI for 22 Days on average.
| MANH | TEM | |
|---|---|---|
Market Cap | $11.79B | $12.77B |
Volume | 393,599 | 8,980,490 |
Sector | Technology | Broad Market / Factor |
52-Week High | $223.76 | $99.28 |
52-Week Low | $120.88 | $41.55 |
Typical Hold Time | 12 Days | 22 Days |
Enterprise Value | $11.66B | $13.40B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MANH trades at $202.11, down 0.36% on the day, with a bearish technical signal and key support at $201. The company shows strong profitability with a net income margin of 18.67% and has beaten earnings estimates for the last three quarters. Recent news includes a law firm investigation into fiduciary duties and a product launch of Editions for its supply chain solutions.
The outlook is mixed: strong fundamentals and analyst buy ratings support upside to the $210.50 consensus target, but technical weakness and the ongoing legal investigation pose near-term risks. Earnings growth remains the key catalyst for further price appreciation.
Tempus AI (TEM) trades at $70.29, down 2.35% on the day, with a bullish technical signal despite negative profitability. Recent FDA clearance for its ECG-MR AI product and 13 abstracts accepted for ESMO Congress 2026 highlight ongoing innovation. Revenue grew to $1.4B in 2026, though net losses persist. The stock shows strong analyst support with a $72.60 consensus target and 64% buy ratings.
Outlook remains cautiously optimistic driven by AI healthcare adoption and data licensing growth, but high valuation multiples and sustained losses pose risks. Investor sentiment is positive amid recent insider selling and institutional interest, yet profitability challenges and competitive pressures require monitoring for long-term value creation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Manhattan Associates Inc
Manhattan Associates, Inc. is a global leader in supply chain and omnichannel commerce software. The company provides a comprehensive suite of cloud-based and on-premise solutions for warehouse management (WMS), transportation management (TMS), and order management (OMS). MANH's technology helps retailers, wholesalers, and manufacturers manage inventory, optimize logistics, and unify the shopping experience across physical and digital channels.
Read more on MANH →About Tempus AI
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →
